We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?
Read MoreHide Full Article
Simulations Plus (SLP - Free Report) shares ended the last trading session 8.9% higher at $30.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.8% loss over the past four weeks.
The increase in share price can be attributed to strong topline performance. Synergies stemming from acquisitions and organic bases are driving the growth trajectory. New customer wins and increasing sales with existing customers of GastroPlus, MonolixSuite and ADMET Predictor offerings are driving the Software segment’s results. Services’ revenues gained from steady growth in QSP and CPP business units.
In the last reported quarter, its organic revenue growth was 14%, eliminating the $2.3 million contribution from Pro-ficiency, which was acquired in June.
For fiscal 2025, Simulations Plus expects revenues to be between $90 million and $93 million. This suggests an increase of 28-33% from fiscal 2024 revenues. The company anticipates continued revenue growth, with organic growth projected between 10% and 15%. In addition, the Pro-ficiency acquisition is expected to contribute an additional $15 million to $18 million to revenues, further boosting the company’s financial outlook.
Simulation Plus recently secured a new grant deal from the U.S. Food and Drug Administration. The funding supports the use of its premium GastroPlus software in physiologically based pharmacokinetic modeling to create and validate mechanistic in vitro-in vivo correlations for long-acting injectable drug technologies. This project is a collaborative effort with the University of Connecticut’s School of Pharmacy, specifically its Department of Pharmaceutical Sciences.
This maker of software used in pharmaceutical research is expected to post quarterly earnings of $0.18 per share in its upcoming report, which represents a year-over-year change of +80%. Revenues are expected to be $18.69 million, up 28.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Simulations Plus, the consensus EPS estimate for the quarter has been revised 105.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SLP going forward to see if this recent jump can turn into more strength down the road.
Simulations Plus is part of the Zacks Computer - Software industry. Autodesk (ADSK - Free Report) , another stock in the same industry, closed the last trading session 2.5% higher at $315.41. ADSK has returned 7.5% in the past month.
Autodesk's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.11. Compared to the company's year-ago EPS, this represents a change of +1.9%. Autodesk currently boasts a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?
Simulations Plus (SLP - Free Report) shares ended the last trading session 8.9% higher at $30.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.8% loss over the past four weeks.
The increase in share price can be attributed to strong topline performance. Synergies stemming from acquisitions and organic bases are driving the growth trajectory. New customer wins and increasing sales with existing customers of GastroPlus, MonolixSuite and ADMET Predictor offerings are driving the Software segment’s results. Services’ revenues gained from steady growth in QSP and CPP business units.
In the last reported quarter, its organic revenue growth was 14%, eliminating the $2.3 million contribution from Pro-ficiency, which was acquired in June.
For fiscal 2025, Simulations Plus expects revenues to be between $90 million and $93 million. This suggests an increase of 28-33% from fiscal 2024 revenues. The company anticipates continued revenue growth, with organic growth projected between 10% and 15%. In addition, the Pro-ficiency acquisition is expected to contribute an additional $15 million to $18 million to revenues, further boosting the company’s financial outlook.
Simulation Plus recently secured a new grant deal from the U.S. Food and Drug Administration. The funding supports the use of its premium GastroPlus software in physiologically based pharmacokinetic modeling to create and validate mechanistic in vitro-in vivo correlations for long-acting injectable drug technologies. This project is a collaborative effort with the University of Connecticut’s School of Pharmacy, specifically its Department of Pharmaceutical Sciences.
This maker of software used in pharmaceutical research is expected to post quarterly earnings of $0.18 per share in its upcoming report, which represents a year-over-year change of +80%. Revenues are expected to be $18.69 million, up 28.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Simulations Plus, the consensus EPS estimate for the quarter has been revised 105.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SLP going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Simulations Plus is part of the Zacks Computer - Software industry. Autodesk (ADSK - Free Report) , another stock in the same industry, closed the last trading session 2.5% higher at $315.41. ADSK has returned 7.5% in the past month.
Autodesk's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.11. Compared to the company's year-ago EPS, this represents a change of +1.9%. Autodesk currently boasts a Zacks Rank of #4 (Sell).